|
1
|
Haddad RI and Shin DM: Recent advances in
head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Overgaard J, Mohanti BK, Begum N, Ali R,
Agarwal JP, Kuddu M, Bhasker S, Tatsuzaki H and Grau C: Five versus
six fractions of radiotherapy per week for squamous-cell carcinoma
of the head and neck (IAEA-ACC study): A randomised, multi-centre
trial. Lancet Oncol. 11:553–560. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roepman P, Wessels LF, Kettelarij N,
Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ,
van der Vliet PC, et al: An expression profile for diagnosis of
lymph node metastases from primary head and neck squamous cell
carcinomas. Nat Genet. 37:182–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weaver A, Fleming S, Ensley J, Kish JA,
Jacobs J, Kinzie J, Crissman J and Al-Sarraf M: Superior clinical
response and survival rates with initial bolus of cisplatin and 120
hour infusion of 5-fluorouracil before definitive therapy for
locally advanced head and neck cancer. Am J Surg. 148:525–529.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rooney M, Kish J, Jacobs J, Kinzie J,
Weaver A, Crissman J and Al-Sarraf M: Improved complete response
rate and survival in advanced head and neck cancer after
three-course induction therapy with 120-hour 5-FU infusion and
cisplatin. Cancer. 55:1123–1128. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang D and Lippard SJ: Cellular processing
of platinum anti-cancer drugs. Nat Rev Drug Discov. 4:307–320.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hall MD, Okabe M, Shen DW, Liang XJ and
Gottesman MM: The role of cellular accumulation in determining
sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol
Toxicol. 48:495–535. 2008. View Article : Google Scholar
|
|
8
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Avruch J, Zhou D, Fitamant J and Bardeesy
N: Mst1/2 signalling to Yap: Gatekeeper for liver size and tumour
development. Br J Cancer. 104:24–32. 2011. View Article : Google Scholar :
|
|
10
|
Wang K, Degerny C, Xu M and Yang XJ: YAP,
TAZ, and Yorkie: A conserved family of signal-responsive
transcriptional coregulators in animal development and human
disease. Biochem Cell Biol. 87:77–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan M, Tomlinson V, Lara R, Holliday D,
Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P,
Danovi SA, et al: Yes-associated protein (YAP) functions as a tumor
suppressor in breast. Cell Death Differ. 15:1752–1759. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vidal M and Cagan RL: Drosophila models
for cancer research. Curr Opin Genet Dev. 16:10–16. 2006.
View Article : Google Scholar
|
|
13
|
Nylander K, Coates PJ and Hall PA:
Characterization of the expression pattern of p63 alpha and delta
Np63 alpha in benign and malignant oral epithelial lesions. Int J
Cancer. 87:368–372. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lo Muzio L, Santarelli A, Caltabiano R,
Rubini C, Pieramici T, Trevisiol L, Carinci F, Leonardi R, De Lillo
A, Lanzafame S, et al: p63 overexpression associates with poor
prognosis in head and neck squamous cell carcinoma. Hum Pathol.
36:187–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan
KH, Li X, Zhou HM and Bhowmick NA: Yes-associated protein
expression in head and neck squamous cell carcinoma nodal
metastasis. PLoS One. 6:e275292011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Y, Khanal P, Savage P, She YM, Cyr TD
and Yang X: YAP-induced resistance of cancer cells to antitubulin
drugs is modulated by a Hippo-independent pathway. Cancer Res.
74:4493–4503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamamura M, Noguchi K, Nakano Y, Segawa E,
Zushi Y, Takaoka K, Kishimoto H, Hashimoto-Tamaoki T and Urade M:
Functional analysis of Zyxin in cell migration and invasive
potential of oral squamous cell carcinoma cells. Int J Oncol.
42:873–880. 2013.PubMed/NCBI
|
|
18
|
Köberle B, Tomicic MT, Usanova S and Kaina
B: Cisplatin resistance: Preclinical findings and clinical
implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
|
|
19
|
Liu AM, Wong KF, Jiang X, Qiao Y and Luk
JM: Regulators of mammalian Hippo pathway in cancer. Biochim
Biophys Acta. 1826:357–364. 2012.PubMed/NCBI
|
|
20
|
Solioz M and Vulpe C: CPx-type ATPases: A
class of P-type ATPases that pump heavy metals. Trends Biochem Sci.
21:237–241. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Culotta VC, Lin SJ, Schmidt P, Klomp LW,
Casareno RL and Gitlin J: Intracellular pathways of copper
trafficking in yeast and humans. Adv Exp Med Biol. 448:247–254.
1999.PubMed/NCBI
|
|
22
|
Katano K, Safaei R, Samimi G, Holzer A,
Rochdi M and Howell SB: The copper export pump ATP7B modulates the
cellular pharmacology of carboplatin in ovarian carcinoma cells.
Mol Pharmacol. 64:466–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samimi G, Katano K, Holzer AK, Safaei R
and Howell SB: Modulation of the cellular pharmacology of cisplatin
and its analogs by the copper exporters ATP7A and ATP7B. Mol
Pharmacol. 66:25–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Safaei R and Howell SB: Copper
transporters regulate the cellular pharmacology and sensitivity to
Pt drugs. Crit Rev Oncol Hematol. 53:13–23. 2005. View Article : Google Scholar
|
|
25
|
Yoshizawa K, Nozaki S, Kitahara H, Ohara
T, Kato K, Kawashiri S and Yamamoto E: Copper efflux transporter
(ATP7B) contributes to the acquisition of cisplatin-resistance in
human oral squamous cell lines. Oncol Rep. 18:987–991.
2007.PubMed/NCBI
|
|
26
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: Key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sudol M and Harvey KF: Modularity in the
Hippo signaling pathway. Trends Biochem Sci. 35:627–633. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu FX and Guan KL: The Hippo pathway:
Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo X and Zhao B: Integration of
mechanical and chemical signals by YAP and TAZ transcription
coactivators. Cell Biosci. 3:332013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lai D, Visser-Grieve S and Yang X: Tumour
suppressor genes in chemotherapeutic drug response. Biosci Rep.
32:361–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carey TE, Van Dyke DL and Worsham MJ:
Nonrandom chromosome aberrations and clonal populations in head and
neck cancer. Anticancer Res. 13(6B): 2561–2567. 1993.PubMed/NCBI
|
|
32
|
Snijders AM, Schmidt BL, Fridlyand J,
Dekker N, Pinkel D, Jordan RC and Albertson DG: Rare amplicons
implicate frequent deregulation of cell fate specification pathways
in oral squamous cell carcinoma. Oncogene. 24:4232–4242. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Visser S and Yang X: Identification of
LATS transcriptional targets in HeLa cells using whole human genome
oligonucleotide microarray. Gene. 449:22–29. 2010. View Article : Google Scholar
|
|
35
|
Kawahara M, Hori T, Chonabayashi K, Oka T,
Sudol M and Uchiyama T: Kpm/Lats2 is linked to chemosensitivity of
leukemic cells through the stabilization of p73. Blood.
112:3856–3866. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Frisch SM, Schaller M and Cieply B:
Mechanisms that link the oncogenic epithelial-mesenchymal
transition to suppression of anoikis. J Cell Sci. 126:21–29. 2013.
View Article : Google Scholar : PubMed/NCBI
|
